Organogenesis: Q3 Earnings Snapshot

Organogenesis (ORGO) reported Q3 2026 revenue of $45.5M, down 70% YoY, with gross margin falling to 52%. The company cut operating expenses by $45M annually and expects Q4 breakeven EBITDA. CEO Gary Eskilhini stated the market has bottomed, with recovery expected by year-end. The company guided 2026 revenue to $179M-$200M, a 65%-68% YoY decline, and expects improving sequential adjusted EBITDA.

Organogenesis reported Q3 cash of $26.9M, down from $94.3M in 2025. It expects 2026 revenue of $179M-$200M, a 65%-68% decline. The company plans $45M in annual cost reductions and $8M for FDA remediation. Amnuvx review and market stabilization were discussed. ORGO shares trade on NASDAQ.

Organogenesis Holdings Inc. reported a 70% YoY revenue decline in Q3, with losses replacing prior-year income. The company's Advanced Wound Care segment contributed most to the drop. FY 2026 guidance suggests a 65%–68% revenue decrease, with a gradual improvement expected in Q4.

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healin

Organogenesis Holdings Inc. (ORGO) reported a net loss of $29.6 million for Q3 2026, a decline from a net income of $21.6 million in Q3 2025. Revenue fell 70% to $45.5 million, with Advanced Wound Care products down 73% and Surgical & Sports Medicine products down 19%. The company expects full-year revenue to decline 65-68% from 2025. Management will discuss results in a conference call.

Organogenesis reported that a peer-reviewed study found its PuraPly AM product, combined with standard care, significantly improved 12-week wound closure in diabetic foot ulcers compared to standard care alone, according to the company.